Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. PRHSX: which is better?

Bottom line

XLV vs PRHSX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 80% by weight.

But PRHSX is far broader, holding 279 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.

XLV is cheaper at 0.08% vs 0.83% — a difference of $75 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +4.2% for PRHSX.

Updated Nov 19, 2026

XLV vs PRHSX side by side

XLVPRHSX
TypeETFMutual fund
Fund familySPDR (State Street)T. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%0.83%
Annual cost per $10k$8$83
10-yr cost on $10k (prospectus)$103$1,025
Max front loadNone—
12b-1 fee0.02%—
1-yr return+14.5%+17.7%
5-yr return (annualized)+8.1%+4.2%
10-yr return (annualized)+9.8%+9.1%
Best quarter+14.5%+23.5%
Worst quarter−12.7%−15.8%
Net assets (fund)$40.6B$11.9B
Number of holdings65279
Portfolio turnover2%62%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVPRHSXDifference
2025+14.5%+17.7%−3.2%
2024+2.5%+1.8%+0.7%
2023+2.0%+3.1%−1.1%
2022−2.1%−12.2%+10.1%
2021+25.9%+13.3%+12.6%
2020+13.3%+30.1%−16.9%
2019+20.7%+29.1%−8.5%
2018+6.3%+1.2%+5.1%
2017+21.7%+28.0%−6.3%
2016−2.8%−10.4%+7.5%

Source: Fund prospectus bar charts

Holdings overlap

17 of XLV's top 25 holdings also appear in PRHSX's top 25.

Shared top holdings
HoldingXLVPRHSX
Eli Lilly & Co16.51%14.28%
Johnson & Johnson10.64%6.63%
AbbVie Inc7.74%5.10%
UnitedHealth Group Inc6.57%5.99%
Merck & Co Inc5.52%4.01%
Amgen Inc3.40%1.82%
Thermo Fisher Scientific Inc3.24%2.52%
Abbott Laboratories2.75%1.89%
Gilead Sciences Inc2.73%2.82%
Intuitive Surgical Inc2.45%1.87%
CVS Health Corp2.30%0.94%
Vertex Pharmaceuticals Inc2.19%2.28%
Danaher Corp2.09%1.43%
Bristol-Myers Squibb Co2.05%2.11%
Stryker Corp1.89%1.78%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

FAQ

What is the difference between XLV and PRHSX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 80% by weight. But PRHSX is far broader, holding 279 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
Which is cheaper, XLV or PRHSX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and PRHSX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.